| 2026-06-03 |
详情>>
股本变动：
变动后总股本8815.85万股
变动原因 ▼▲
- 原因：
- Common stock offered 5,660,378 shares by the company
|
| 2026-05-18 |
详情>>
内部人交易：
Rodman David Malcom共交易2笔
|
| 2026-05-06 |
详情>>
业绩披露：
2026年一季报每股收益-0.47美元,归母净利润-3933.9万美元,同比去年增长6.80%
|
| 2026-05-06 |
财报披露：
美东时间 2026-05-06 盘后发布财报
|
| 2026-04-08 |
股东大会：
将于2026-05-21召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve as Class III directors for a three-year term to expire at the 2029 annual meeting of stockholders;
2.To ratify the appointment of Ernst & Young LLP as Mineralys Therapeutics, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2026;
3.To transact such other business as may properly come before the meeting or any adjournment(s) thereof.
|
| 2026-03-12 |
详情>>
业绩披露：
2025年年报每股收益-2.29美元,归母净利润-1.55亿美元,同比去年增长13.02%
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.94美元,归母净利润-1.22亿美元,同比去年增长5.00%
|
| 2025-08-12 |
详情>>
业绩披露：
2025年中报每股收益-1.44美元,归母净利润-8548.5万美元,同比去年增长-17.87%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益-0.79美元,归母净利润-4221.1万美元,同比去年增长-33.97%
|
| 2025-04-09 |
股东大会：
将于2025-05-22召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve as Class II directors for a three-year term to expire at the 2028 annual meeting of stockholders;
2.To ratify the appointment of Ernst & Young LLP as Mineralys Therapeutics, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To transact such other business as may properly come before the meeting or any adjournment(s) thereof.
|
| 2025-03-10 |
复牌提示：
2025-03-10 06:55:00 停牌，复牌日期 2025-03-10 07:30:00
|
| 2025-02-12 |
详情>>
业绩披露：
2024年年报每股收益-3.66美元,归母净利润-1.78亿美元,同比去年增长-147.31%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.68美元,归母净利润-1.29亿美元,同比去年增长-171.24%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-1.54美元,归母净利润-7252.2万美元,同比去年增长-193.03%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.7美元,归母净利润-3150.8万美元,同比去年增长-149.9%
|
| 2024-04-09 |
股东大会：
将于2024-05-22召开股东大会
会议内容 ▼▲
- 1.To elect one director to serve as a Class I director for a three-year term to expire at the 2027 annual meeting of stockholders;
2.To ratify the appointment of Ernst & Young LLP as Mineralys Therapeutics, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To transact such other business as may properly come before the meeting or any adjournment(s) thereof.
|
| 2024-03-21 |
详情>>
业绩披露：
2023年年报每股收益-1.99美元,归母净利润-7189.8万美元,同比去年增长-141.28%
|